WASHINGTON — The Association for Accessible Medicines strongly supports President Biden’s America’s Supply Chains Executive Order as an important step toward strengthening the U.S. pharmaceutical supply chain and improving patient access to lower-cost generic and biosimilar medicines. The Executive Order is a prudent, considered approach to fully understanding the scope and capacity of current U.S. pharmaceutical manufacturing, while identifying specific vulnerabilities that can be targeted for resolution both immediately with the COVID-19 pandemic and longer-term as the country prepares for future public health challenges.
The U.S. government plays a critical role in encouraging the conditions that support domestic manufacturing of essential medicines. AAM believes that additional incentives, such as those included in our Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain, will be necessary as the U.S. seeks to increase its role in the global pharmaceutical supply chain.
AAM member companies, who currently employ approximately 52,000 American workers manufacturing more than 60 billion generic doses annually at 149 facilities across the country, believe that with the right incentives in place, even more American workers can contribute to a secure U.S. supply chain.
For more information about AAM and their solutions, visit www.secureourmeds.org.